At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing the Impact of Control-IQ Technology on Quality of Life and Glycemic Control in Children and Youth With Type 1 Diabetes in a Canadian Context
In Brief
An observational study for Type 1 Diabetes. Completed, enrolled 65 participants across 1 site.
Detailed Summary
This is a single-centre, mixed-methods, prospective study in pediatric patients with T1D initiating Control-IQ technology on the Tandem t-slim X2 insulin pump. Primary Objective: To determine pediatric T1D patients' and their parents' perceptions of the impact of Control-IQ on their psychosocial functioning and quality of life.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesCanada
CollaboratorsTandem Diabetes Care, Inc.
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedApr 2021
Primary CompletionOct 2021
TodayJul 2026
First PostedApr 9, 2021
Enrollment StartMar 15, 2021
Primary CompletionOct 26, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.2 years ago